There is nothing better than looking back at all the articles for the past year and seeing what you, our readers, liked best. This past year, with the help of our great staff and over 40 PharmD candidates, we were able to deliver more than 1,400 articles, facts, interviews, slide presentations, opinions and features.

We sat down this past week and looked at the most popular for the whole year. We learned that as a drug class, the SGLT-2 inhibitors generated more interest than any other class of medications. In fact, the response to this class was so overwhelming that we are going to dedicate a full issue to looking at the most popular SGLT-2 I selections next week.

This week we have the most viewed items for 2015. As sometimes happens, what looks like a big story and a game changer in the first part of the year can often turn out to be only a blip on the diabetes radar screen. February’s and March’s most read articles certainly prove that, and October’s best could be a great indication of the future of diabetes care.

I asked a patient with erratic glucose levels where he usually gave his insulin injections to which he responded, “In my arms.” I asked, “Could you show me where?” The patient promptly rolled up his sleeves and pointed to the vein in his antecubital space.

There is nothing better than looking back at all the articles for the past year and seeing what you, our readers, liked best. This past year, with the help of our great staff and over 40 PharmD candidates, we were able to deliver more than 1,400 articles, facts, interviews, slide presentations, opinions and features.

We sat down this past week and looked at the most popular for the whole year. We learned that as a drug class, the SGLT-2 inhibitors generated more interest than any other class of medications. In fact, the response to this class was so overwhelming that we are going to dedicate a full issue to looking at the most popular SGLT-2 I selections next week.

This week we have the most viewed items for 2015. As sometimes happens, what looks like a big story and a game changer in the first part of the year can often turn out to be only a blip on the diabetes radar screen. February’s and March’s most read articles certainly prove that, and October’s best could be a great indication of the future of diabetes care.

I asked a patient with erratic glucose levels where he usually gave his insulin injections to which he responded, “In my arms.” I asked, “Could you show me where?” The patient promptly rolled up his sleeves and pointed to the vein in his antecubital space.